Immunogenic HSV-mediated Oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy

Molecular Therapy

Volumn 22, Issue 1, 2014, Pages 123-131

  Workenhe, Samuel T ^a   Simmons, Graydon ^a   Pol, Jonathan G ^a   Lichty, Brian D ^a   Halford, William P ^b   Mossman, Karen L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL LEVEL; CELL METABOLISM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OSTEOSARCOMA; PROTEIN SECRETION; TUMOR VOLUME; VIRAL CLEARANCE; VIRUS IDENTIFICATION; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

ANIMALS; ANTIGEN-PRESENTING CELLS; APOPTOSIS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HMGB1 PROTEIN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MUTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECEPTOR, ERBB-2; SIMPLEXVIRUS; TUMOR BURDEN; VIRUS REPLICATION;

EID: 84891825541     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.238     Document Type: Article

References (37)

1. Vähä-Koskela, MJ, Heikkilä, JE and Hinkkanen, AE (2007). Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216
2. Russell, SJ, Peng, KW and Bell, JC (2012). Oncolytic virotherapy. Nat Biotechnol 30: 658-670
3. Martuza, RL, Malick, A, Markert, JM, Ruffner, KL and Coen, DM (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856
4. Mossman, KL and Smiley, JR (2002). Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication. J Virol 76: 1995-1998
5. Mossman, KL, Saffran, HA and Smiley, JR (2000). Herpes simplex virus ICP0 mutants are hypersensitive to interferon. J Virol 74: 2052-2056
6. Hummel, JL, Safroneeva, E and Mossman, KL (2005). The role of ICP0-Null HSV-1 and interferon signaling defects in the effective treatment of breast adenocarcinoma. Mol Ther 12: 1101-1110
7. Sobol, PT, Boudreau, JE, Stephenson, K, Wan, Y, Lichty, BD and Mossman, KL (2011). Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy. Mol Ther 19: 335-344
8. Pandha, H, Melcher, A, Harrington, K and Vile, R (2009). Oncolytic viruses: Time to compare, contrast, and combine? 5th international meeting on replicating oncolytic virus therapeutics. Banff, Alberta, Canada, 18-22 March 2009. Mol Ther 17: 934-935
9. Wollmann, G, Tattersall, P and Van Den Pol, AN (2005). Targeting human glioblastoma cells: Comparison of nine viruses with oncolytic potential. J Virol 79: 6005-6022
10. Bennett, JJ, Delman, KA, Burt, BM, Mariotti, A, Malhotra, S, Zager, J et al. (2002). Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther 9: 935-945
11. Halford, WP, Püschel, R and Rakowski, B (2010). Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: Implications for a genital herpes vaccine. PLoS ONE 5: E12251
12. Prestwich, RJ, Errington, F, Diaz, RM, Pandha, HS, Harrington, KJ, Melcher, AA et al. (2009). The case of oncolytic viruses versus the immune system: Waiting on the judgment of Solomon. Hum Gene Ther 20: 1119-1132
13. Ma, Y, Adjemian, S, Mattarollo, SR, Yamazaki, T, Aymeric, L, Yang, H et al. (2013). Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38: 729-741
14. Kroemer, G, Galluzzi, L, Kepp, O and Zitvogel, L (2013). Immunogenic cell death in cancer therapy. Annu Rev Immunol 31: 51-72
15. Krysko, DV, Garg, AD, Kaczmarek, A, Krysko, O, Agostinis, P and Vandenabeele, P (2012). Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12: 860-875
16. Obeid, M, Tesniere, A, Ghiringhelli, F, Fimia, GM, Apetoh, L, Perfettini, JL et al. (2007). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61
17. Zappasodi, R, Pupa, SM, Ghedini, GC, Bongarzone, I, Magni, M, Cabras, AD et al. (2010). Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death. Cancer Res 70: 9062-9072
18. Diaconu, I, Cerullo, V, Hirvinen, ML, Escutenaire, S, Ugolini, M, Pesonen, SK et al. (2012). Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 72: 2327-2338
19. Donnelly, OG, Errington-Mais, F, Steele, L, Hadac, E, Jennings, V, Scott, K et al. (2013). Measles virus causes immunogenic cell death in human melanoma. Gene Ther 20: 7-15
20. Kono, H and Rock, KL (2008). How dying cells alert the immune system to danger. Nat Rev Immunol 8: 279-289
21. Sidera, K, Gaitanou, M, Stellas, D, Matsas, R and Patsavoudi, E (2008). A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 283: 2031-2041
22. Qin, Z, DeFee, M, Isaacs, JS and Parsons, C (2010). Extracellular Hsp90 serves as a co-factor for MAPK activation and latent viral gene expression during de novo infection by KSHV. Virology 403: 92-102
23. Multhoff, G and Hightower, LE (2011). Distinguishing integral and receptor-bound heat shock protein 70 (Hsp70) on the cell surface by Hsp70-specific antibodies. Cell Stress Chaperones 16: 251-255
24. Daniels, GA, Sanchez-Perez, L, Diaz, RM, Kottke, T, Thompson, J, Lai, M et al. (2004). A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 22: 1125-1132
25. Sanchez-Perez, L, Kottke, T, Daniels, GA, Diaz, RM, Thompson, J, Pulido, J et al. (2006). Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol 177: 4168-4177
26. Yanai, H, Ban, T, Wang, Z, Choi, MK, Kawamura, T, Negishi, H et al. (2009). HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature 462: 99-103
27. Dumitriu, IE, Baruah, P, Manfredi, AA, Bianchi, ME and Rovere-Querini, P (2005). HMGB1: Guiding immunity from within. Trends Immunol 26: 381-387
28. Guo, ZS, Liu, Z, Bartlett, DL, Tang, D and Lotze, MT (2013). Life after death: Targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res 3: 1-20
29. Toda, M, Rabkin, SD, Kojima, H and Martuza, RL (1999). Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10: 385-393
30. Wong, RJ, Patel, SG, Kim, S, DeMatteo, RP, Malhotra, S, Bennett, JJ et al. (2001). Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma. Hum Gene Ther 12: 253-265
31. Zager, JS, Delman, KA, Malhotra, S, Ebright, MI, Bennett, JJ, Kates, T et al. (2001). Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol Med 7: 561-568
32. Miller, CG and Fraser, NW (2003). Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model. Mol Ther 7: 741-747
33. Nakamori, M, Fu, X, Rousseau, R, Chen, SY and Zhang, X (2004). Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther 9: 658-665
34. Workenhe, ST, Pol, JG, Lichty, BD, Cummings, DT and Mossman, KL (2013). Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy. Cancer Immunol Res doi:10.1158/2326-6066.CIR-13-0059-T (epub ahead of print).
35. Rovero, S, Amici, A, Di Carlo, E, Bei, R, Nanni, P, Quaglino, E et al. (2000). DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165: 5133-5142
36. Summers, BC and Leib, DA (2002). Herpes simplex virus type 1 origins of DNA replication play no role in the regulation of flanking promoters. J Virol 76: 7020-7029
37. Grinshtein, N, Ventresca, M, Margl, R, Bernard, D, Yang, TC, Millar, JB et al. (2009). High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome. Cancer Gene Ther 16: 338-350